TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression
International Journal of Biological Sciences · 2023
DOI: 10.7150/ijbs.78738 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2023. Verfasst von Araceli López-Tejada und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Transforming Growth Factor beta, Triple Negative Breast Neoplasms, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
In triple-negative breast cancer (TNBC), the pleiotropic NDRG1 (N-Myc downstream regulated gene 1) promotes progression and worse survival, yet contradictory results were documented, and the mechanisms remain unknown. Phosphorylation and localization could drive NDRG1 pleiotropy, nonetheless, their role in TNBC progression and clinical outcome was not investigated. We found enhanced p-NDRG1 (Thr346) by TGFβ1 and explored whether it drives NDRG1 pleiotropy and TNBC progression. In tissue microarrays of 81 TNBC patients, we identified that staining and localization of NDRG1 and p-NDRG1 (Thr346) are biomarkers and risk factors associated with shorter overall survival. We found that TGFβ1 leads NDRG1, downstream of GSK3β, and upstream of NF-κB, to differentially regulate migration, invasion, epithelial-mesenchymal transition, tumor initiation, and maintenance of different populations of cancer stem cells (CSCs), depending on the progression stage of tumor cells, and the combination of TGFβ and GSK3β inhibitors impaired CSCs. The present study revealed the striking importance to assess both total NDRG1 and p-NDRG1 (Thr346) positiveness and subcellular localization to evaluate patient prognosis and their stratification. NDRG1 pleiotropy is driven by TGFβ to differentially promote metastasis and/or maintenance of CSCs at different stages of tumor progression, which could be abrogated by the inhibition of TGFβ and GSK3β.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain.
- GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.
- Instituto de Investigación Biosanitaria ibs.GRANADA, University Hospitals of Granada-University of Granada, Spain; Conocimiento s/n 18100, Granada. Spain.
- UGC de Oncología Médica, Hospital Universitario de Jaén, 23007 Jaén, Spain.
- UGC de Anatomía Patológica, Hospital Universitario de Jaén, Jaén, Spain.
- FIBAO, Hospital Universitario de Jaén, Servicio Andaluz de Salud, Jaén, Spain.
Zitieren
APA
López-Tejada, A., Griñán-Lisón, C., González-González, A., Cara, F. E., Luque, R. J., Rosa-Garrido, C., Blaya-Cánovas, J. L., Navarro-Ocón, A., Valenzuela-Torres, M., Parra-López, M., Calahorra, J., Blancas, I., Marchal, J. A., & Granados-Principal, S. (2023). TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.78738
Vancouver
López-Tejada A, Griñán-Lisón C, González-González A, Cara FE, Luque RJ, Rosa-Garrido C, et al. TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression. International Journal of Biological Sciences. 2023. doi:10.7150/ijbs.78738
BibTeX
@article{LpezTejada2023,
author = {López-Tejada, Araceli and Griñán-Lisón, Carmen and González-González, Adrián and Cara, Francisca E and Luque, Rafael J and Rosa-Garrido, Carmen and Blaya-Cánovas, José L and Navarro-Ocón, Alba and Valenzuela-Torres, María and Parra-López, Marisa and Calahorra, Jesús and Blancas, Isabel and Marchal, Juan A and Granados-Principal, Sergio},
title = {TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression},
journal = {International Journal of Biological Sciences},
year = {2023},
doi = {10.7150/ijbs.78738}
}
EUVIMED